Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common dose-limiting side effects of cancer treatment, affecting 30-70% of patients receiving neurotoxic chemotherapy agents. It can develop during treatment, peak after completion, and in many patients persist permanently. The walking consequences are significant and often underappreciated by oncology teams focused on tumour response metrics.
Chemotherapy Agents Most Commonly Causing CIPN
- Taxanes (paclitaxel, docetaxel, cabazitaxel): Cause sensory neuropathy, predominantly affecting large fibres (proprioception, vibration sense). Patients lose fine balance feedback from their feet
- Platinum compounds (cisplatin, oxaliplatin, carboplatin): Cause sensory neuropathy; oxaliplatin also causes acute cold-triggered neuropathic pain that can affect walking in cold weather
- Vinca alkaloids (vincristine, vinblastine, vinorelbine): Cause mixed sensory and motor neuropathy -- foot weakness and foot drop may occur alongside sensory loss
- Bortezomib and other proteasome inhibitors: Cause predominantly sensory neuropathy in myeloma treatment
- Thalidomide and lenalidomide: Used in myeloma; both cause peripheral neuropathy
CIPN Gait Features
The gait changes in CIPN reflect the underlying nerve damage:
- Reduced proprioception causes a stomping gait -- the patient slams the foot down to generate ground-contact feedback that normal proprioception would provide automatically
- Reduced vibration sense and position sense leads to Romberg-positive balance (falls when eyes are closed or in poor lighting)
- Motor involvement (particularly from vinca alkaloids) causes foot drop and ankle weakness
- Increased fall risk -- CIPN patients fall at higher rates than non-CIPN cancer patients
Walking Cane Role After Chemotherapy
- Proprioceptive supplement: The cane provides a supplementary ground-contact signal through the hand and arm. Research on peripheral neuropathy balance shows that even light cane contact substantially improves balance in sensory neuropathy patients
- Stomping gait modification: A cane that is correctly placed provides an anticipatory stability signal before the foot lands, reducing the need for stomping
- Night and low-light safety: CIPN patients have high fall risk in reduced lighting when visual compensation for proprioceptive loss is reduced. A cane provides tactile grounding in these conditions
CIPN and Cane Use
| CIPN Feature | Walking Impact | Cane Role |
|---|---|---|
| Reduced proprioception | Romberg-positive, stomping gait | Supplementary somatosensory signal; anticipatory stability |
| Reduced vibration sense | Balance on uneven surfaces | Additional contact anchor on terrain changes |
| Cold-triggered pain (oxaliplatin) | Winter walking especially limited | Stability during pain episodes; ice tip for cold surfaces |
| Motor weakness/foot drop (vincristine) | Foot drag, trip risk | Contralateral cane; AFO may supplement |
| Night walking | Visual compensation for neuropathy lost | Cane essential in reduced lighting |
Explore the DaiWalk cane collection. Related: Walking Cane for Peripheral Neuropathy | Walking Cane for Cancer-Related Fatigue
